Preserving the efficacy of antibiotics to tackle antibiotic resistance
Microbial Biotechnology · 2024-07 · 17 (7)
DOI: 10.1111/1751-7915.14528 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, online erschienen am 17.07.2024. Verfasst von Pablo Laborda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteria, Bacterial Infections, Drug Resistance, Bacterial. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MCIN/AEI /10.13039/501100011033, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Different international agencies recognize that antibiotic resistance is one of the most severe human health problems that humankind is facing. Traditionally, the introduction of new antibiotics solved this problem but various scientific and economic reasons have led to a shortage of novel antibiotics at the pipeline. This situation makes mandatory the implementation of approaches to preserve the efficacy of current antibiotics. The concept is not novel, but the only action taken for such preservation had been the ‘prudent’ use of antibiotics, trying to reduce the selection pressure by reducing the amount of antibiotics. However, even if antibiotics are used only when needed, this will be insufficient because resistance is the inescapable outcome of antibiotics' use. A deeper understanding of the alterations in the bacterial physiology upon acquisition of resistance and during infection will help to design improved strategies to treat bacterial infections. In this article, we discuss the interconnection between antibiotic resistance (and antibiotic activity) and bacterial metabolism, particularly in vivo, when bacteria are causing infection. We discuss as well how understanding evolutionary trade‐offs, as collateral sensitivity, associated with the acquisition of resistance may help to define evolution‐based therapeutic strategies to fight antibiotic resistance and to preserve currently used antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
- Department of Biology, Emory University, Atlanta, Georgia, USA.
- Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
ORCID-Profile: Pablo Laborda, Teresa Gil-Gil, José Luis Martínez, Sara Hernando-Amado
Förderung
- MCIN/AEI /10.13039/501100011033
- Ministerio de Ciencia e Innovación
Zitieren
APA
Laborda, P., Gil-Gil, T., Martínez, J. L., & Hernando-Amado, S. (2024). Preserving the efficacy of antibiotics to tackle antibiotic resistance. Microbial Biotechnology, 17(7). https://doi.org/10.1111/1751-7915.14528
Vancouver
Laborda P, Gil-Gil T, Martínez JL, Hernando-Amado S. Preserving the efficacy of antibiotics to tackle antibiotic resistance. Microbial Biotechnology. 2024;17(7). doi:10.1111/1751-7915.14528
BibTeX
@article{Laborda2024,
author = {Laborda, Pablo and Gil-Gil, Teresa and Martínez, José Luis and Hernando-Amado, Sara},
title = {Preserving the efficacy of antibiotics to tackle antibiotic resistance},
journal = {Microbial Biotechnology},
year = {2024},
volume = {17},
number = {7},
doi = {10.1111/1751-7915.14528}
}
EUVIMED